Anti-IgE therapy with omalizumab reduces serum levels of free IgE and downregulates
expression of IgE receptors (FcεRI) on mast cells and basophils. In the airways of patients with …

An estimated 300 million people are affected by asthma worldwide and the burden is likely
to rise substantially in the next few decades. Estimates of the prevalence of asthma range …

Background Triple fixed-dose regimens of an inhaled glucocorticoid, a long-acting
muscarinic antagonist (LAMA), and a long-acting β 2 -agonist (LABA) for chronic obstructive …

Study objectives: To compare the efficacy and safety of the inhaled corticosteroid
fluticasone propionate (FP) and the inhaled long-acting β 2 -agonist salmeterol (SM), when …

Background Inhaled corticosteroids have been used in patients with chronic obstructive
pulmonary disease (COPD), but the potential benefits of their use in triple therapy are not well …

Rationale: In the phase III, 52-week ETHOS (Efficacy and Safety of Triple Therapy in
Obstructive Lung Disease) trial in chronic obstructive pulmonary disease (COPD) (NCT02465567), …

Chronic obstructive pulmonary disease (COPD) is the end result of a series of dynamic and
cumulative gene–environment interactions over a lifetime. The evolving understanding of …

Rationale: Moderate and severe exacerbations are incompletely prevented by maximal
inhalation therapy in patients with severe chronic obstructive pulmonary disease. Objectives: To …

Background Long-acting muscarinic antagonist (LAMA)/long-acting β 2 -agonist (LABA)
combinations are a treatment option for patients with COPD who continue to have symptoms …

Background Ventilator-associated pneumonia caused by Pseudomonas aeruginosa (PA) in
hospitalised patients is associated with high mortality. The effectiveness of the bivalent, …